Kala Bio (Kala Bio) EBIT per Share : $-12.93 (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Kala Bio EBIT per Share?

Kala Bio's EBIT per Share for the three months ended in Mar. 2024 was $-3.68. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-12.93.

During the past 3 years, the average EBIT per Share Growth Rate was 46.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was 32.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Kala Bio's EBIT per Share or its related term are showing as below:

KALA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -37.9 Med: 15.5 Max: 46.4
Current: 46.4

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Kala Bio was 46.40% per year. The lowest was -37.90% per year. And the median was 15.50% per year.

KALA's 3-Year EBIT Growth Rate is ranked better than
92.03% of 1305 companies
in the Biotechnology industry
Industry Median: 3.5 vs KALA: 46.40

Kala Bio's EBIT for the three months ended in Mar. 2024 was $-10.35 Mil.

Kala Bio EBIT per Share Historical Data

The historical data trend for Kala Bio's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kala Bio EBIT per Share Chart

Kala Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-125.54

-91.35

-102.00

-24.69

-14.96

Kala Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-6.27	-3.77	-2.84	-2.64	-3.68

Kala Bio EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Kala Bio's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-36.385	/	2.432
=	-14.96

Kala Bio's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-10.352	/	2.813
=	-3.68

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.93

Kala Bio (NAS:KALA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Kala Bio EBIT per Share Related Terms

Thank you for viewing the detailed overview of Kala Bio's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Kala Bio (Kala Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (NAS:KALA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

27F0:Germany

Address

1167 Massachusetts Avenue, Arlington, MA, USA, 02476

Website

https://www.kalarx.com

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Executives

Todd Bazemore	officer: Chief Operating Officer	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Romulus K Brazzell	officer: Chief Medical Officer	C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Eric Trachtenberg	officer: See Remarks	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Darius Kharabi	officer: CHIEF BUSINESS OFFICER	C/O KALA PHARMACEUTICALS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Mark T Iwicki	director, officer: Chief Executive Officer	84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Mary Reumuth	officer: Chief Financial Officer	100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Marjan Farid	director	C/O KALA PHARMACEUTICALS, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON MA 02476
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Mark S. Blumenkranz	director	C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Hongming Chen	officer: Chief Scientific Officer	100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
C. Daniel Myers	director	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Gregory Grunberg	director	100 BEAVER STREET, WALTHAM MA 02453
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116